Safety profile of lasmiditan in patients with migraine in an Asian population
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2087630
Abstract: ABSTRACT Background MONONOFU, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of Japanese patients with migraine, was pivotal for lasmiditan approval in Japan. However, treatment-emergent adverse events (TEAEs) were more common than in global studies.… read more here.
Keywords: safety; patients migraine; profile lasmiditan; teaes ... See more keywords